Research programme: antibacterial fixed-dose combination therapies - AstraZeneca/FOB Synthesis

Drug Profile

Research programme: antibacterial fixed-dose combination therapies - AstraZeneca/FOB Synthesis

Alternative Names: Beta lactamase inhibitor/Carbapenem - AstraZeneca/FOB Synthesis; Beta lactamase inhibitor/FSI-1671 - AstraZeneca/FOB Synthesis; Beta lactamase inhibitor/FSI-1686 - AstraZeneca/FOB Synthesis

Latest Information Update: 30 Jan 2014

Price : $50

At a glance

  • Originator AstraZeneca; FOB Synthesis
  • Class Carbapenems
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 27 Jan 2014 Preclinical trials in Gram-negative infections in USA (unspecified route)
  • 27 Jan 2014 Preclinical trials in Gram-negative infections in United Kingdom (unspecified route)
  • 27 Jan 2014 AstraZeneca and FOB Synthesis enter into a option and license agreement to co-develop fixed-dose combination therapies in the UK and the US for bacterial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top